1009 related articles for article (PubMed ID: 32293834)
1. Antiviral treatment of COVID-19.
Şimşek Yavuz S; Ünal S
Turk J Med Sci; 2020 Apr; 50(SI-1):611-619. PubMed ID: 32293834
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Costanzo M; De Giglio MAR; Roviello GN
Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
[TBL] [Abstract][Full Text] [Related]
3. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Uzunova K; Filipova E; Pavlova V; Vekov T
Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
[TBL] [Abstract][Full Text] [Related]
4. Treatment options for COVID-19: The reality and challenges.
Jean SS; Lee PI; Hsueh PR
J Microbiol Immunol Infect; 2020 Jun; 53(3):436-443. PubMed ID: 32307245
[TBL] [Abstract][Full Text] [Related]
5. An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.
Wang D; Li Z; Liu Y
J Infect Public Health; 2020 Oct; 13(10):1405-1414. PubMed ID: 32684351
[TBL] [Abstract][Full Text] [Related]
6. Race to find COVID-19 treatments accelerates.
Kupferschmidt K; Cohen J
Science; 2020 Mar; 367(6485):1412-1413. PubMed ID: 32217705
[No Abstract] [Full Text] [Related]
7. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Martinez MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
[TBL] [Abstract][Full Text] [Related]
8. [Chloroquine as a possible treatment for COVID-19].
Coumou J; de Vries PJ
Ned Tijdschr Geneeskd; 2020 Mar; 164():. PubMed ID: 32391999
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Data of Current Therapies for SARS-CoV-2.
Anastasiou IA; Eleftheriadou I; Tentolouris A; Tsilingiris D; Tentolouris N
Curr Med Chem; 2020; 27(27):4542-4548. PubMed ID: 32400323
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
Sanders JM; Monogue ML; Jodlowski TZ; Cutrell JB
JAMA; 2020 May; 323(18):1824-1836. PubMed ID: 32282022
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
Liu W; Zhou P; Chen K; Ye Z; Liu F; Li X; He N; Wu Z; Zhang Q; Gong X; Tang Q; Du X; Ying Y; Xu X; Zhang Y; Liu J; Li Y; Shen N; Couban RJ; Ibrahim QI; Guyatt G; Zhai S
CMAJ; 2020 Jul; 192(27):E734-E744. PubMed ID: 32493740
[TBL] [Abstract][Full Text] [Related]
12. Psychopharmacology of COVID-19.
Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL
Psychosomatics; 2020; 61(5):411-427. PubMed ID: 32425246
[TBL] [Abstract][Full Text] [Related]
13. Potential therapeutic agents against COVID-19: What we know so far.
Lu CC; Chen MY; Lee WS; Chang YL
J Chin Med Assoc; 2020 Jun; 83(6):534-536. PubMed ID: 32243270
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review.
Jomah S; Asdaq SMB; Al-Yamani MJ
J Infect Public Health; 2020 Sep; 13(9):1187-1195. PubMed ID: 32773212
[TBL] [Abstract][Full Text] [Related]
15. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
Barlow A; Landolf KM; Barlow B; Yeung SYA; Heavner JJ; Claassen CW; Heavner MS
Pharmacotherapy; 2020 May; 40(5):416-437. PubMed ID: 32259313
[TBL] [Abstract][Full Text] [Related]
16. Treatment of SARS-CoV-2: How far have we reached?
Ahsan W; Javed S; Bratty MA; Alhazmi HA; Najmi A
Drug Discov Ther; 2020 May; 14(2):67-72. PubMed ID: 32336723
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
18. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
Choy KT; Wong AY; Kaewpreedee P; Sia SF; Chen D; Hui KPY; Chu DKW; Chan MCW; Cheung PP; Huang X; Peiris M; Yen HL
Antiviral Res; 2020 Jun; 178():104786. PubMed ID: 32251767
[TBL] [Abstract][Full Text] [Related]
19. [From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic].
Estella Á; Garnacho-Montero J
Med Intensiva (Engl Ed); 2020 Nov; 44(8):509-512. PubMed ID: 32423569
[No Abstract] [Full Text] [Related]
20. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
